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ABSTRACT

As a secondary analysis of the VAST-D clinical trial data, we employed a multi-layered
strategy to describe the complicated clinical features of Major Depressive Disorder (MDD) and
the heterogeneity among depressive symptoms, using the following analytical approaches:
(1) Cluster analysis was used to transform a large and heterogenous mix of survey questions into
a small number of correlated MDD symptom clusters: Four robust and highly-interpretable MDD
symptom clusters (core emotional, appetite and weight, sleep disorders, atypical) were identified
within the VAST-D trial, consistent with the findings from other relevant studies.
(2) Decision tree analysis was used to identify symptom thresholds with particularly effective
discriminability in identifying remitters who were being treated with the three different study
medications. Classification trees built for remission using a CART algorithm, were used for each
of the three treatments and for the total cohort in the VAST-D study to facilitate:
(a) Generation of practical guidance that could be used to inform decision-making in real clinical
settings;
(b) Identification of features for the sub-groups of patients showing low/high responses to each of
the three treatments;
(c) Identification of the most important factors for remission through the use of random forests.

Key words: Major Depressive Disorder, symptom cluster, CART, decision tree, random forest,
patient subtyping, Biostatistics
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I.

BACKGROUND

A. Major Depressive Disorder
Major depressive disorder (MDD, “depression”) espouses a spectrum of different
symptoms spread across many axes of daily living, including mood, appetite, fatigue and
socialization, each with their own range of severities.1,2 MDD affects approximately 16% of the
U.S. population at some point in their lives, however, only less than one-third of patients achieve
remission with their first antidepressant.3,4 It is believed that a combination of biological,
psychological, genetic and social factors are the major causes in the onset of a depressive condition.
However, the exact cause and pathophysiology of MDD is not yet understood, and as a result
prescription of treatment regimen remains empiric.
Different rating scales have been developed to diagnose MDD and to measure symptom
severity. All the commonly-used rating scales assess each of the nine DSM-IV-TR criterion
symptom domains5 (Sleep disturbance, Sad mood, Appetite/weight, Concentration, Self-criticism,
Suicidal ideation, Interest, Energy/fatigue, Psychomotor agitation/ retardation) with varying
designs. While the extant rating scales have demonstrated great facility in diagnosing MDD, there
is great interest in studying the structure and relative importance of each of these surveys,
particularly for synergizing plural information sources for the sake of prioritizing treatments.

B. The VAST-D Clinical Trial for treatment of MDD
Given the fact that only less than one-third of patients with MDD respond to their first
antidepressant treatment and achieve remission, next-step treatments are in great demand for the
large number of unresponsive patients. The VA Augmentation and Switching Treatments for
Improving Depression Outcomes (VAST-D) – a multisite randomized, single-blind, parallel-group
trial – was conducted to determine the relative effectiveness of three common alternate next-step
treatments in patients whose MDD was unresponsive to prior antidepressant treatments. A total of
1,522 veterans (mean age, 54.4 years; men, 1296 [85.2%]) were randomized to one of the three
interventions – Switch to a different antidepressant, bupropion (n = 511); augment current
treatment with bupropion (n = 506); or augment with an atypical antipsychotic, aripiprazole
(n = 505). After a 12-week follow-up period, 28.9% participants in the augment-aripiprazole group,
26.9% in the augment-bupropion group and 22.3% in the switch-to-bupropion group achieved
remission respectively. The only significant, although modest, remission comparison was found
between the augment-aripiprazole group and the switch-to-bupropion group. Full study design and
results of the primary analysis are published elsewhere in detail.6,7

C. Thesis Objectives
Objective 1.a: To identify similar symptoms within Major Depressive Disorder by investigating
its underlying grouping schemes, i.e. symptom clusters;
Objective 1.b: To compare the grouping schemes of baseline MDD symptoms identified in our
study and in other relevant studies: whether the groupings are robust across different studies using
different diagnostic tools and study populations.

Objective 2: To construct decision trees for remission for the three different study medications
respectively. Based on the decision trees and relevant tree-based analyses, (a) to identify subgroups of patients showing low or high responsiveness within each study arm, and to pinpoint key
features with thresholds distinguishing different sub-groups; (b) to identify the most important
factors for remission by random forests.

D. Overview of approach
We first applied hierarchical clustering, an unsupervised machine learning method, to
identify baseline symptom clusters. The symptom clusters captured the most important and concise
information of depressive symptoms with reduced dimensions. That is, symptom cluster scores
were further derived as informative and succinct summary of diverse MDD symptoms, by
averaging the scores of multiple symptoms within the same cluster. After combining the newlyderived symptom clusters information with other baseline data, we conducted decision tree
analyses for each treatment group and for the study cohort as a whole: (a) The Classification and
Regression Tree (CART) model was used to build single decision trees for remission for each
treatment respectively. The graphical representation of possible remission status with certain
conditions on patient features could be highly intuitive, especially in a clinical context.
(b) Random forest, an ensemble machine learning method that aggregates the results of multiple
single decision trees with less overfitting tendency yet less intuitive results, was then applied as a
complement to single trees. The Importance of Variable indices evaluated by random forest were
used to identify the most important factors for remission. Finally, we offered new insights into
underlying structures of MDD symptoms and sub-groups of patients or specific symptoms that
show high- or low-likelihood of treatment response to anti-depressants in general.

a. Symptom Clustering
Given the clinical diversity of MDD symptoms, it is essential, to investigate underlying
coherent clusters of these diverse symptoms. The reduced symptom dimensions would not only
provide insight into the underlying nature of the complex disorder, but also assist a great many
relevant next-step studies and make the findings more interpretable. Some approximately
consistent clusters of depression symptoms were identified in recent studies with different rating
scales and different statistical approaches 8-10. Using data collected in the VAST-D study, we
replicated these symptom clusters and evaluated the robustness of the clusters identified across
different studies. Our study will be the first to merge data from two different instruments together
(PHQ-9 and QIDS-C16). By comparing the results from a merged dataset versus clusters obtained
independently from a single instrument, we will provide valuable insight into the results obtained
by others, specifically: do the different clusters obtained by various authors reflect their choices of
diagnostic tool.
Factor analysis and clustering are two major statistical methods for investigating
underlying grouping schemes and relationships of various symptoms. Compared to factor analysis
that produces complicated structural relationships between individual symptoms and higher-level
groups (called factors in factor analysis), hierarchical clustering produces more concise results
where each individual symptom is only assigned to one single cluster. We applied hierarchical
clustering in the study for its simplicity of interpreting and visualizing results, given that our main
purpose is to investigate the underlying grouping schemes of complicated depressive symptoms.
To summarize, we first applied hierarchical clustering, an unsupervised machine learning
method, to examine the baseline symptom clusters. Then we compared our symptom clusters to
the ones identified in other studies.

b. Decision Tree Analyses
Due to the complexity of MDD and heterogeneity among depressive symptoms patients,
some treatments tend to exhibit differential effectiveness with different patient groups. Many
studies have been conducted to show promising evidence of subtypes of MDD based on biological
variables or on clinical features11, indicating potential personalized diagnostics and medication
strategies of MDD.12 However, research results diffuse slowly into clinical practice. In addition,
remembering or even evaluating each treatment guideline on an individual symptom level is
complicated and inefficient in clinical practice.
Decision trees are a popular supervised machine learning technique, especially useful for
classification problems. Tree-based learning algorithms are adept at producing high classification
accuracy with very concise representation of gathered knowledge.13-15 The use of machine learning
methods including decision tree techniques to assist in medical diagnosis, decision-making and
prediction of medical and health conditions has received substantial attention from researchers in
recent years.16-19 Further, being non-parametric, tree based techniques afford great flexibility (i.e.
no constraints on the data type, no assumptions about the space distribution and the classifier
structure) compared to other conventional modeling methods.
With an interest in facilitating knowledge translation into clinical practice, our study
implemented decision tree analyses to make highly intuitive and easy-to-implement guidelines for
individualized treatment selections from the three alternative MDD anti-depressant treatment
strategies in the VAST-D trial, and to identify sub-groups of patients or specific symptoms that
show high- or low-likelihood of treatment response to each anti-depressant. To the best of our
knowledge, ours is the first analytical approach that investigates MDD antidepressant therapy
through the use of decision tree techniques.

II.

METHODS
The study is a secondary analysis of the VAST-D randomized clinical trial. The primary

objective of the VAST-D trial was to evaluate the effectiveness and safety of three treatment
approaches for MDD.6,7
A. VAST-D: Protocol summary and Study Population
Participants were recruited from 35 VA medical centers. Patients were considered eligible
for VAST-D if they had an MDD diagnosis, were non-responsive to at least one course of antidepressant treatment, and capable and willing to provide informed consent. The criterion for study
entry was a score of 16 or more (indicating severe depression) on the Quick Inventory of
Depressive Symptomatology-Clinician Rated (QIDS-C16) questionnaire after at least 6 weeks of
treatment, or a score of 11 or more (indicating moderately severe depression) after at least 8 weeks
of treatment with the three most recent weeks at a stable “optimal” dose.
Patients were randomized to one of three treatments in a 1:1:1 ratio: switch to another
antidepressant, namely bupropion sustained release (Sw; Randomized as Treatment A),
augmentation of current treatment with bupropion sustained release (AB; Randomized as
Treatment B), or augment current treatment with aripiprazole (AA; Randomized as Treatment C).
A total of 1,522 study participants completed the study protocol and their remission status
on or before Week 12 was determined. The primary outcome was remission (1=remission, 0= no
remission), defined as a QIDS-C16 score of 5 or less at 2 consecutive scheduled follow-up visits
during the acute treatment phase.

B. Study Data
In the study, we included all the 1522 participants who completed the study protocol of the
VAST-D trial. The outcome measure in our study is the remission status (1=remission, 0=no
remission), which is the primary outcome defined in the original VAST-D study. For the variables,
we considered available baseline information included demographic information, smoking history
and frequency, depression related information, vital signs of health, medication use,
psychopathology assessments, adverse effect assessments, quality-of-life assessments, and the
PHQ-9 patient Depression Questionnaire. A full description of all variables and instruments
included in the study is shown in Appendix A.

C. Statistical Analysis
a.

Symptom Clustering
PHQ-9 and QIDS-C16 are the two instruments used in this part of analysis (See Appendix

A for instrument descriptions). To measure the severity of MDD symptoms, there is a one-to-one
correspondence between the nine items of the PHQ-9 questionnaire and the nine DSM-IV-TR
domains of MDD symptoms. Further, there is a one/multiple-to-one correspondence between the
sixteen items of the QIDS-C16 questionnaire and the nine domains. The rating scales are the same
for all items within both questionnaires, ranging from 0 (least severity) to 3 (most severity). For
the MDD symptom domains (Sleep, Appetite/Weight, Psychomotor) which are each measured by
multiple items in the QIDS-C16 questionnaire, the domain score is the highest score among its
related items.
To obtain a more high-resolution dataset of the MDD symptoms, we focused on the 16
MDD symptoms instead of the 9 symptom domains in the analysis. To obtain a more balanced

view of the severity of each symptom, we averaged the corresponding clinician-rated and selfrated symptom scores, of each patient. Based on the averaged scores, hierarchical clustering
(Distance measure: Euclidean distance; Cluster agglomeration method: Ward’s method) was
applied to identify the underlying clusters of symptoms.
b. Decision Tree Analyses
1. CART Modeling
Using clinical and demographic data (see Appendix A), and the computed symptom cluster
scores (average the symptom scores of each symptom cluster), classification and regression trees
(CARTs) algorithms were applied to construct decision tree models. For each treatment group and
for the total cohort, classification trees utilizing the CART algorithm were intended for the primary
outcome (: 1 = remission, 0 = no remission).
A decision tree is a hierarchically organized structure, with each node partitioning the
predictor space into disjoint subspaces based on value of a predictor. And same decisions/
predictions are made for all data points on the same predictor subspace.
The decision tree modeling mainly comprises two processes: splitting and pruning. The
splitting process produces fully-grown trees utilizing the CART algorithm. The algorithm makes
top-down recursive binary division of the predictor space into partitions. Each split is created after
considering all the possible splits at each node by examining each predictor in turn. Then to choose
the best split so that the resulting child nodes are the “purest”, measured by the reduction in an
impurity index (Gini Index) with respect to the response.
A pruning process follows the partitioning process to prevent potential overfitting issues
by trimming the nodes of the tree in a bottom-up fashion: The fully-grown decision trees are further

pruned back based on a cost-complexity algorithm, producing smaller trees with better crossvalidation properties.
2. Random Forest
Though highly interpretable, single trees are prone to over-fitting; thus, random forests
were also evaluated to give more convincing results. Random forest is a versatile and powerful
machine learning technique that mitigates possible overfitting problems of decision trees with
robust results, by aggregating the results of a large number of uncorrelated decision trees (number
of bootstrapped trees in the study: 500) into one final result. As the basic building block of a
random forest, each classification tree is created by randomly selecting a pre-specified number of
variables from all predictors in each splitting process without pruning (Number of variables at
each split in the study: 9).
Moreover, as a powerful dimensionality reduction method, random forest is adept at
handling large data set with higher dimensionality and identifying the most significant predictors.
It generates an index for each predictor variable representing the relative importance of that
variable, in terms of Importance of Variable. Based on the importance index of each variable, we
investigated most important factors (Top 10) for remission, respectively for each treatment group
and for the total cohort.
c.

Software and packages
We conducted all the analyses in R software. The “hclust” package was used for

hierarchical clustering for symptom cluster analyses. The “rpart” package was used for building
CART trees and the “randomForest” package was used for random forest analysis for the decision
tree analyses.

III.

RESULTS AND DISCUSSION

A. Symptom Clustering
We found four highly-interpretable symptom clusters among the sixteen MDD symptoms
that measure the nine symptom domains (Figure 1). The four symptom clusters comprise core
emotional

symptom

cluster

(bad

mood,

concentration/decision

making,

loss

of

interest/involvement, feelings of worthless/self-outlook, energy/fatigability), appetite and weight
symptom cluster (weight/appetite increases/decreases), symptom cluster of sleep disorders (sleeponset Insomnia, early morning insomnia, mid-nocturnal insomnia, hypersomnia) and atypical
symptom cluster (psychomotor agitation/slowing, suicidal ideation).
More importantly, our finding shared a great consistency with the MDD symptom
groupings found in other studies, adding value to the confidence of the theory of MDD symptom

Figure 1 Dendrogram: Four MDD symptom clusters (baseline) identified by hierarchical clustering in the VAST-D study.

clusters (Table 2). Romera8 performed factor analysis of the Zung self-rating depression scale
(ZSDS) and found a clinical interpretable 4-factor structure – a core depressive factor, a cognitive
factor, an anxiety factor and a somatic factor – respectively correspond to the core emotional,
atypical, sleep and appetite/weight symptom clusters in our study. Li 9 found three meaningful
factors reflecting weight/appetite disturbance, general depressive symptoms and sleep disturbance
– respectively correspond to the appetite/weight, core emotional, symptom clusters in our study –
by means of exploratory and confirmatory factor analysis in a large sample of 6008 depressed Han
Chinese women. Chekroud8 reported three robust symptom clusters - the sleep symptom cluster,
core emotional symptom cluster and atypical cluster – validated with three data settings (QID-SR
scale used in the STAR*D trial, QID-SR scale used in the CO-MED trial, HAM-D scale used in
the STAR*D trial) by hierarchical clustering.
Similar grouping schemes of diverse MDD symptoms were obtained by various studies
using different instruments and were reproduced within VAST-D in our study. Therefore, these
MDD symptom clusters are suggested to be robust given different choices of instruments or
diagnostic tools. Besides uncovering the underlying nature of MDD symptoms, these meaningful
symptom clusters could fuel relevant studies by condensing the information and/or reducing the
dimension of diverse MDD symptoms. They could also assist clinicians with more concise
knowledge of the list of MDD symptoms collected by different questionnaires in the clinical
context.

Table 1Summary of symptom clustering in three recent secondary analyses and our study

Our study
VAST-D
Agglomerative
(bottom-up)
hierarchical clustering

Romera, 20089
Caballero, 200820
Unweighted
exploratory factor
analysis

Li, 201310
CONVERGE21
Exploratory and
confirmatory factor
analysis

PHQ-9 and QIDS-C16

ZSDS22

DSM-IV

Core Emotional
▪
▪
▪
▪

▪

Bad mood
Energy/fatigability
Concentration/decision
making
Loss of interest
Feelings of
worthlessness/selfoutlook

Core Depressive
▪
▪
▪
▪
▪
▪
▪

▪

Sleep
▪
▪
▪

▪

Mid-nocturnal
insomnia
Sleep-onset insomnia
Early morning
insomnia
Hypersomnia

▪

▪
▪

Psychomotor
retardation
Psychomotor agitation
Suicidal ideation

▪
▪

Appetite and weight

▪

Loss of appetite
Loss of weight
Increase of appetite
Increase of weight

▪
▪

▪

Depressed mood
Anhedonia
Psychomotor
retardation
Psychomotor
agitation
Loss of energy or
fatigue
Feeling of
worthlessness

Core Emotional
▪
▪
▪
▪
▪

Sleep disturbance
▪

▪

Insomnia
Hypersomnia

▪

▪

▪
▪

Mid-nocturnal
insomnia
Sleep-onset
insomnia
Early morning
insomnia

▪
▪
▪

Weight/appetite
▪
▪
▪
▪

Loss of appetite
Loss of weight
Increase of appetite
Increase of weight

Psychomotor
retardation
Psychomotor
agitation
Suicidal ideation
Hypersomnia

Bad mood
Energy/fatigability
Concentration/
Decision-making
Loss of interest
Feelings of
worthlessness/
Self-outlook

▪
▪
▪
▪

▪

Sleep
▪
▪
▪

Atypical
▪

Psychomotor
retardation
Fatigue
Confusion
Indecisiveness

Decreased appetite
Weight loss
Tachycardia

▪
▪
▪

Sleep
▪

▪

Somatic factor
▪
▪

Bad mood
Energy/fatigability
Concentration/
Decision-making
Loss of interest
Feelings of
worthlessness/
Self-outlook

HAM-D28 in
STAR*D
Core Emotional

QIDS-SR in COMED
Core Emotional

QIDS-SR in STAR*D

Cognitive
▪

▪

▪
▪
▪

Sleep disturbance
Psychomotor
agitation
Irritability

Agglomerative (bottom-up)
hierarchical clustering

General depressive
▪
▪
▪

Anxiety
▪
▪

Atypical
▪

Depressed affect
Crying spells
Decreased libido
Hopelessness
Personal
devaluation
Emptiness
Suicidal rumination
Dissatisfaction

Chekroud, 20178
STAR*D23-25 and CO-MED26,27

Mid-nocturnal
insomnia
Sleep-onset
insomnia
Early morning
insomnia

Sleep
▪
▪
▪

▪

Atypical
▪
▪
▪
▪

Psychomotor
retardation
Psychomotor
agitation
Suicidal ideation
Hypersomnia

Somatic anxiety
Psychological
anxiety
Guilt and delusions
Sad mood
Loss of interest

Mid-nocturnal
insomnia
Sleep-onset
insomnia
Early morning
insomnia
Energy/fatigability

Atypical
▪
▪
▪
▪
▪

Psychomotor
slowing
Psychomotor
agitation
Suicide
Reduced libido
Hypochondriasis

B. Decision Tree Analyses
a. CART modeling
Classification decision trees were built based on the CART algorithm, respectively for the
three treatment groups and for the total cohort. In each situation, the predicted outcome (remission
or not) for a certain patient could be quickly obtained by going through a decision path of some
certain simple conditions.
Figure 2 Classification trees for each of the three treatment groups in the VAST-D study (algorithm: CART).
Within each node, the predicted outcome is in the first line: 0 – not remit, 1 – remit. The two decimals in the
second line are the remission rate. Percentages in the third line is the proportion of participants in this node.

Treatment A (Switch
to bupropion
sustained release)
Treatment
A
1

0
0.22
100%
yes

PHQ9 Total Score >= 7.5

no

3

1
0.65
6%
Core Emotional Symptom
Cluster Score >= 1.4

2

6

7

0
0.20
94%

0
0.27
2%

1
0.85
4%

Treatment B (Augment
with
B bupropion sustained release)
Treatment
1

0
0.27
100%
yes

QIDS Total Score >= 16 no
3

0
0.42
39%
Agitation Score (PHQ9) < 2.5
6

0
0.39
37%
BAI Total Score >= 14
13

0
.50 .50
19%
PMH Score < 16

2

12

26

27

7

0
0.17
61%

0
0.27
18%

0
0.33
8%

1
0.62
11%

1
0.83
2%

Treatment C (Augment with aripiprazole)
Treatment C
0
0.29
100%
yes Core Emotional Symptom no

Cluster Score >= 2

3

0
0.48
38%
Mid-nocturnal Insomnis
Score (QIDS) >= 0.5

6

0
0.42
32%
BAI Total Score >= 12

2

12

13

7

0
0.17
62%

0
0.31
21%

1
0.61
11%

1
0.80
6%

1. Personalized treatment selection from the three treatments in VAST-D
Here, we put forward an intuitive and easy to implement guideline for clinicians to make
personalized treatment selection from the three MDD treatments in the VAST-D study, and the
logic could be extended to other existing treatments if data available:
(1) For a given patient, a clinician could quickly go through the decision tree and record the
predicted result (remission or not and/or probability of remission) under each of the treatment
scenarios.
(2) Then summarize the predicted results over the three (or more) treatments and make the
selection.
For example, a patient is predicted to remit for treatment A while not to remit for treatment
B or C. Obviously, treatment A would be the suggested individualized treatment for that patient.
Likewise, a treatment would be suggested if its predicted probability of remission is obviously
higher than the predicted remission probabilities of other treatments.
Naturally, classifiers derived from group analyses yield probabilistic statements about a
deterministic phenomenon: the patient will either remit or not, and the probability can only provide
a statement about the likelihood of an individual outcome given a knowledge-based obtained from
others. In these situations, the guideline is still valuable to simply and quickly exclude or screen
out some treatments with based on the best available information. The final decision could then be
made by incorporating clinician expertise and patient preferences.

2. Highly responsive/unresponsive sub-groups of MDD patients
Sub-groups of patients or specific symptoms that show high- or low-likelihood of treatment
response to anti-depressants were identified by evaluating the terminal nodes of each classification
tree using the VAST-D data.
For a decision tree, the feature space of all terminal nodes is mutually exclusive and
collectively exhaustive, and each terminal node represents a group of patients with similar features
indicated by its previous nodes. By evaluating the average remission rate and proportion of patients
of that terminal node, we distinguished highly responsive/unresponsive sub-groups of MDD
patients. Comparisons were based on the results of the primary analysis in the VAST-D study:
The remission rate of treatment A is 22.3%; The remission rate of treatment B is 26.9%;
The remission rate of treatment C is 28.9%.

Table 2 Features of highly unresponsive subgroups of MDD patients within each treatment group
(There is no highly unresponsive subgroup identified for treatment A)

Highly unresponsive sub-groups of MDD patients for Treatment B
(Overall remission rate of treatment B: 26.9%)

Sub-group b1
(Sub-group remission rate 17%; Proportion of the treatment group 61%)
Conditions
Interpretation
Higher levels of clinician-rated depressive
QIDS Total Score < 16
symptoms in general

Highly unresponsive sub-groups of MDD patients for Treatment C
(Overall remission rate of treatment C: 28.9%)

Sub-group c1
(Sub-group remission 17%; Proportion of the treatment group 62%)
Conditions
Interpretation
Core Emotional Symptom Cluster Score >= 2

Higher levels of core emotional symptoms

Table 3 Features of Highly responsive subgroups of MDD patients within each treatment group

Highly responsive sub-groups of MDD patients for Treatment A
(Overall remission rate of treatment A: 22.3%)

Sub-group A1
(Sub-group remission rate 85%; Proportion of the treatment group 4%)
Conditions
Interpretation
Lower levels of patient self-rated depressive symptoms
PHQ-9 total Score < 7.5
in general
&
&
Core Emotional Symptom Cluster Score < 1.4
Lower levels of core emotional symptoms

Highly responsive sub-groups of MDD patients for Treatment B
(Overall remission rate of treatment B: 26.9%)

Sub-group B1
(Sub-group Remission rate 83%; Proportion of the treatment group 2%)
Conditions
Interpretation
Lower levels of clinician-rated depressive
QIDS Total Score < 16
symptoms in general
&
&
PHQ-9 Agitation Item Score >= 2.5
Higher levels of patient-rated psychomotor agitation

Sub-group B2
(Sub-group remission rate 62%; Proportion of the treatment group 11%)
Conditions
Interpretation
Lower levels of clinician-rated depressive
QIDS Total Score < 16
symptoms in general
&
&
PHQ-9 Agitation Item Score < 2.5
Lower levels of patient-rated psychomotor agitation
&
&
BAI Total Score < 12
Lower levels of self-report anxiety in general
&
&
Positive Mental Health Score > 16
Higher levels of positive mental health

Highly responsive sub-groups of MDD patients for Treatment C
(Overall remission rate of treatment C: 28.9%)

Sub-group C1
(Sub-group remission rate 80%; Proportion of the treatment group 6%)
Conditions
Core Emotional Symptom Cluster Score < 2
&
QIDS Mid-nocturnal Item Score < 0.5

Interpretation
Lower levels of core emotional symptoms
&
Lower levels of mid-nocturnal symptoms

Sub-group C2
(Sub-group remission rate 61%; Proportion of the treatment group 11%)
Conditions
Interpretation
Core Emotional Symptom Cluster Score < 2
Lower levels of core emotional symptoms
&
&
BAI Total Score < 12
Lower levels of self-report anxiety in general
&
&
QIDS Mid-nocturnal Item Score >= 0.5
Higher levels of mid-nocturnal symptoms

b. Random Forest: Important factors for Remission
According to the Importance of Variable indices by random forests, we evaluated ten most
important variables in predicting the binary outcome (remission), respectively for each treatment
group and for the total cohort. BAI (Beck Anxiety Inventory) total score, duration of trial and BMI
are the three most important factors for remission for treatment A; BAI total score, duration of
trial and age are the three most important factors for remission for treatment B; QIDS total score,
BAI total score and core emotional symptom cluster score are the three most important factors for
remission for treatment C; BAI total score, QIDS total score, BMI are the three most important
factors for remission in general.
An interesting finding is the consistency of significant variables across situations: The four
situations have exactly the same ten most important factors for remission with different rankings.
The great consistency may implicate most important factors for MDD remission, and fuel related
studies concerning a dimensional reduction or model selection process.
In a clinical context, these top factors could assist clinicians to make rough but quick
judgement of how probable the remission would occur for a patient in general and/or for each
treatment.

Figure 3 Random Forest Results – Ten most important factors for remission according to the Importance of Variable index

Table 4 Detail information of the ten significant factors for remission.

CoreEmotScore

Score of the core emotional symptom cluster

CIRSscore

Total score of the Cumulative Illness Rating Scale

phq9TotScore

Total score of the Patient Health Questionnaire

CIRSseverity_index

Severity index of the Cumulative Illness Rating Scale

PosHlthscore

Score of the Positive Mental Health instrument

AGE

Age of the patient

BMI

Body Mass Index (WeightLb/(HeightIn*HeightIn))*703

Dur_Trial_Months

Duration of index treatment trial (months)

qidsTotalscore

Total score of the 16-item Quick Inventory of Depressive Symptomatology

baiTotScore

Total Score of the Beck Anxiety Inventory

C. Limitations
The biggest limitation of the study is the inability to generalize the findings: First, potential
solutions included in the proposed guidelines for the individualized treatment selection of MDD
are limited to the three treatments in the VAST-D trial. However, it is likely that more alternate
treatments are considered in a real situation. On the other hand, the guidelines could be easily
extended to more solutions by the same framework if data available. Second, decision trees are
prone to overfitting. That is, the trees may have better performance in predicting the outcome for
the VAST-D trial data than for new data. Although the pruned trees with smaller number of layers
in our study could reduce the likelihood of the problem theoretically, the robustness of the treebased models is expected to be further tested and validated in other relevant studies. Third, older
male VA patients predominated in the study participants (mean age, 54.4 years; men, 1296
[85.2%]). Therefore, whether the results could be further generalized to a broader population is
unknown. To adjust the results for a broader population, analysis on different study populations
using same or similar procedures is suggested. Another concern is that the VAST-D studied
patients who had already failed at least one medication, and therefore, the results from our study
may not be appropriate for newly diagnosed MDD patients. We expect to apply same or similar
procedures proposed in our study on MDD patients with their first treatments. And if our technique
could be extended to studies of first-line medication for MDD treatments, it would be a great
opportunity to decrease the first-time failure rates.
Improvements could be made in the findings of most important factors for MDD remission
identified in our study using random forests: Besides the relative importance of each factor, more
informative results could be obtained if the magnitude and direction of influence on remission of
each factor were complemented. Integrating the results of a logistic regression or cox regression

model on the same VAST-D study data is suggested in the next step analysis to: 1) provide
supplemental information (magnitudes and signs of coefficients) that how the important variables
identified by random forest influence the results (remission); 2) compare the significant variables
from regression models (may after a model selection procedure) with the important variables from
random forests and investigate the consistency and difference. And new insights are expected by
comparing our results using random forests within VAST-D study to other studies with similar
purposes based on different statistical methods and data setting.

IV.

CONCLUSION
In the study, we first applied hierarchical clustering on the baseline data of the VAST-D
trial and identified four highly-interpretable clusters for the sixteen MDD symptoms included in
the PHQ-9 and QIDS-C16 questionnaires. The four symptom clusters (core emotional, appetite
and weight, sleep disorders, atypical) share great consistency with the findings from other studies
using other different MDD instruments and/or statistical methods. Therefore, our findings provide
new evidence in support of the theory of symptom clusters of MDD by reproducing the grouping
schemes of MDD symptoms in the PHQ-9 and QIDS-C16 instruments.
In support of knowledge translation and clinical application via MDD personalized
treatment selection, we are the first to implement decision tree analytical techniques in this field
and to propose an easy-to-implement and dependable guideline in a clinical context. Compared to
most regression models for similar study objectives that produce significance levels and
coefficients for each covariates, decision tree models are easy to understand and interpret for
people with or without statistical background, and their graphical display could be easily
interpreted and adopted in the clinical setting. By quickly going through the three decision trees

generated in the study based on the CART algorithm, an individualized treatment suggestion
among the three alternative anti-depressants could be obtained for each MDD patient. Of course,
the final treatment decision should consider other important factors including clinicians'
experience and judgement and significant findings from other studies. Subgroups of patients with
similar features that have specific high/low response to each treatment within the VAST-D trial
were also evaluated from the decision trees.
Finally, we screened out ten most important factors from a great many factors for MDD
remission using random forests. Together with the findings of the four robust symptom clusters,
valuable insights into the underlying structure of complicated MDD symptoms and other related
features are proposed that could assist in clinical management of patients.

V.

Appendix A

Following patient-level data were included in the analysis:
▪

Patient study number, randomized group assignment and participating site number,
duration of index treatment trial in months, outcomes (=1 remission, =0 not remission);

▪

Demographics: age, sex, marital status, education level, employment, race, ethnics; health
status (BMI, alcohol/drug use history and frequency, total score and severity index of the
CIRS);

▪

Psychopathology assessments include total scores of the QIDS-C16, PHQ-9, PMH and BAI
instruments; indicators of recurrent mania or depressant, and PTSD; the CGI-Severity
index;

▪

MDD symptom scores and nine DSM-IV-TR criterion symptom domains scores:

-

For the PHQ-9 instrument, the nine symptom scores (score of each item) are the nine
corresponding symptom domain scores.

-

For the QIDS-C16 instrument, there are 16 MDD symptom scores (scores of the 16
items) and 9 symptom domain scores: If there is a one-to-one correspondence between
the item and the MDD symptom domain, then the domain score is the item score, if
there is a multiple-to-one correspondence between the items and the symptom domain,
then the domain score is the highest score of the items of that domain)

Table for Appendix A. Brief description of measures used in the study

Instrument

QIDS-C1628

PHQ-929

Description
A 16-item clinician-rated depression scale that adopts a
4-point scale: 0 – 3, higher scores indicate higher degree of
severity of that depression symptom during the past 7 days.
The 16 items have a one/multiple-to-one correspondence
to the nine DSM-IV symptom criterion domains: Sleep
disturbance domain - Initial, middle, and late insomnia or
16-item Quick hypersomnia (Q1-Q4), Sad mood domain (Q5), Appetite/
Inventory of
weight domain - Decrease/increase in appetite/weight (Q6Depressive
Q9), Concentration domain (Q10), Self-criticism domain
Symptomatology (Q11), Suicidal ideation domain (Q12), Interest domain
(Q13), Energy/fatigue domain (Q14), Psychomotor
domain – Psychomotor agitation/retardation (Q15-16).
The score of each domain is the highest score of the items
within that domain. And the total score of the instrument is
the sum of all the nine domain scores, indicating the
severity of depression.
A 9-item self-report depression scale that adopts a 4-point
scale (0 – 3, higher scores indicate higher frequencies of
being bothered by that item during the last 2 weeks), where
Patient Health
each item corresponds to each of the nine DSM-IV-TR
Questionnaire
criterion symptom domains. The total score is the sum of
the 9 items. Higher scores indicate higher degree of
severity of MDD.

PMH30

Positive Mental
Health
Instrument

BAI31

Beck Anxiety
Inventory

32

CGI-Severity

CIRS33

VI.

Clinical Global
Impressions
Severity Index
Cumulative
Illness Rating
Scale

A 47-item instrument included six subscales: general
coping (9 items), emotional support (7 items), spirituality
(7 items), interpersonal skills (9 items), personal growth
and autonomy (10 items), and global affect (5 items).
Higher scores indicate higher PMH.
A 21-item self-report anxiety scale adopts a 4-point scale
(0 = not at all, 1 = mildly, 2 = moderately, 3 = severely).
The total score is the sum of the 21 items (0-21 = low
anxiety, 22-35 = moderate anxiety, 36 or above =
potentially concerning levels of anxiety). Higher scores
indicate higher self-report measure of anxiety.
A one-item clinician-rated index that evaluates the severity
of psychopathology from 1(least severe) to 7 (most
severe).
One of the commonly used tools to measure comorbidity
that measures the chronic medical illness burden with the
severity of chronic diseases considered. Higher score
indicates higher severity.
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